Amyloid targeting agents and methods of using the same

Patent metadata

Field	Value
Publication number	US-10934264-B2
Application number	US-201916439505-A
Country	US
Kind code	B2
Filing date	Jun 12, 2019
Priority date	Mar 19, 2014
Publication date	Mar 2, 2021
Grant date	Mar 2, 2021

Abstract

Provided herein is the design and synthesis of novel molecular rotor fluorophores useful for detection of amyloid or amyloid like proteins. The fluorophores are designed to exhibit enhanced fluorescence emission upon associating with amyloid or amyloid like proteins as compared to unbound compound. Also disclosed herein are methods for treating diseases associated with amyloid or amyloid like proteins.

First claim

What is claimed is:

1. A compound of Formula (Ic), a pharmaceutically acceptable salt thereof, or a solvate thereof:

wherein:
EDG is heterocycloalkyl of no more than 10 carbon atoms optionally substituted with one or more R 17 ;
each R17 is independently halogen, —OR 18 , —NR 19 R 20 , C 1 -C 10 alkyl, or C 1 -C 10 heteroalkyl;
each of R 18 , R 19 , and R 20 is independently hydrogen, C 1 -C 10 alkyl, C 1 -C 10 heteroalkyl, or cycloalkyl of no more than 10 carbon atoms, each of which except for hydrogen is optionally substituted with one or more R 21 ;
each R 21 is independently halogen, —OR 22 , —NR 23 R 24 , C 1 -C 10 alkyl, C 1 -C 10 heteroalkyl, cycloalkyl of no more than 10 carbon atoms, heterocycloalkyl of no more than 10 carbon atoms, aryl of no more than 10 carbon atoms, or heteroaryl of no more than 10 carbon atoms;
each of R 22 , R 23 , and R 24 is independently hydrogen or C 1 -C 10 alkyl;
Ar is naphthyl optionally substituted with one or more R 1 ;
each R 1 is independently halogen, —OR 2 , —NR 3 R 4 , C 1 -C 10 alkyl, or C 1 -C 10 heteroalkyl,
each of R 2 , R 3 , and R 4 is independently hydrogen, C 1 -C 10 alkyl, or C 1 -C 10 heteroalkyl;
R 84 is hydrogen or C 1 -C 10 alkyl;
EWG is —CN;
WSG is

n is an integer from 2 to 10;
R 81 is hydrogen;
X is C═O; and
Y is NH.

2. The compound of claim 1 , wherein EDG is:

3. The compound claim 1 , wherein EDG is heterocycloalkyl having 6 ring atoms.

4. The compound claim 1 , wherein EDG is unsubstituted.

5. The compound claim 1 , wherein EDG is

6. The compound of claim 1 , wherein n is 3.

7. The compound of claim 1 , wherein R 84 is hydrogen.

8. The compound of claim 1 , wherein R 84 is methyl.

9. The compound of claim 1 , wherein Ar is

10. A pharmaceutical composition comprising the compound of claim 1 , the pharmaceutically acceptable salt thereof, or the solvate thereof, and a pharmaceutically acceptable excipient.

11. The pharmaceutical composition of claim 10 , wherein the pharmaceutically acceptable excipient is ethanol, dimethyl sulfoxide, polyethylene glycol, polypropylene glycol, aqueous acetate buffer, aqueous citrate buffer, aqueous phosphate buffer, aqueous carbonate buffer, a cyclodextrin, corn oil, vitamin E, a polysorbate, polyethyleneglycol-15 hydroxystearate, a bile acid, or a combination of two or more thereof.

12. A method for monitoring response to a treatment of a patient having a disease or condition characterized by amyloid deposit in a body part or a body area of the patient, the method comprising:
(i) forming a detectable complex in the body part or the body area following the treatment by contacting an effective amount of the compound of claim 1 , the pharmaceutically acceptable salt thereof, or the solvate thereof, or a pharmaceutical composition thereof, with the amyloid deposit; and
(ii) detecting the detectable complex, wherein a decrease of detectable complex as compared to before treatment indicates that the patient is responsive to treatment.

13. The method of claim 12 , in which the amyloid deposit comprises an amyloid or amyloid like protein, wherein the amyloid or amyloid like protein is Aβ peptide, prion peptide, alpha-synuclein, or superoxide dismutase.

14. The method of claim 13 , wherein the amyloid or amyloid like protein is beta amyloid (1-42) (Aβ(1-42)).

15. The method of claim 12 , wherein the disease or condition is Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Lewy body dementia, or Down's syndrome.

16. The method of claim 12 , wherein the disease or condition is a prion disease.

17. The method of claim 12 , wherein the disease or condition is Creutzfeldt-Jakob disease.

18. A method for monitoring the response of a patient having a disease or condition characterized by amyloid deposit to a treatment, the method comprising
(i) forming a detectable complex following the treatment by contacting an effective amount of a compound of the formula:

or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a pharmaceutical composition thereof, with a sample, a body part, or a body area of the patient; and

(ii) detecting the formation of the detectable complex, wherein a decrease of detectable complex as compared to before the treatment indicates that the patient is responsive to the treatment;

wherein the disease or condition is selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Lewy body dementia, Down's syndrome, and Creutzfeldt-Jakob disease.

19. A method of detecting an amyloid or amyloid like protein, the method comprising
(i) contacting the compound of formula (Ic), a pharmaceutically acceptable salt thereof, or a solvate thereof with a sample potentially comprising the amyloid or amyloid like protein, wherein in presence of an amyloid or amyloid like protein the compound forms a detectable complex; and
(ii) detecting the formation of the detectable complex such that the presence or absence of the detectable complex correlates with the presence or absence of the amyloid or amyloid like protein;
wherein the compound of Formula (Ic) is:

wherein
EDG is heterocycloalkyl of no more than 10 carbons optionally substituted with one or more R 17 ;
wherein each R 17 is independently halogen, —OR 18 , —NR 19 R 20 , C 1 -C 10 alkyl, or C 1 -C 10 heteroalkyl;
each of R 18 , R 19 , and R 20 is independently hydrogen, C 1 -C 10 alkyl, C 1 -C 10 heteroalkyl, or cycloalkyl of no more than 10 carbon atoms, each of which except for hydrogen is optionally substituted with one or more R 21 ;
each R 21 is independently halogen, —OR 22 , —NR 23 R 24 , C 1 -C 10 alkyl, C 1 -C 10 heteroalkyl, cycloalkyl of no more than 10 carbon atoms, heterocycloalkyl of no more than 10 carbon atoms, aryl of no more than 10 carbon atoms, or heteroaryl of no more than 10 carbon atoms;
each of R 22 , R 23 , and R 24 is independently hydrogen or C 1 -C 10 alkyl;
Ar is aryl of no more than 14 carbon atoms optionally substituted with one or more R 1 ;
each R 1 is independently halogen, —OR 2 , —NR 3 R 4 , C 1 -C 10 alkyl, or C 1 -C 10 heteroalkyl,
each of R 2 , R 3 , and R 4 is independently hydrogen, C 1 -C 10 alkyl, or C 1 -C 10 heteroalkyl;
R 84 is hydrogen or C 1 -C 10 alkyl;
EWG is halogen, —CN, —NO 2 , or methyl;
WSG is:

n is an integer from 2 to 50,
R 81 is hydrogen, a C 1 -C 10 alkyl, a C 2 -C 10 alkenyl, or a C 2 -C 10 alkynyl, wherein the alkyl,

Assignees

• Univ California
• Amydis Inc

Inventors

• Yang Jerry
• Theodorakis Emmanuel A
• Sarraf Stella

Classifications

• C07D413/12

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D409/14

  containing three or more hetero rings · CPC title

• C07D211/06

  having no double bonds between ring members or between ring members and non-ring members · CPC title

• C07D407/10

  linked by a carbon chain containing aromatic rings · CPC title

• C07H13/04

  having the esterifying carboxyl radicals attached to acyclic carbon atoms · CPC title